Table 3. Changes from baseline in parasite load until 12 months of follow up in parasite load, conventional serology and AT CL-ELISA.
| Placebo (n=47) |
LD (n=48) |
SD (n=46) |
HD (n=45) |
BZN (N=45) |
|
|---|---|---|---|---|---|
| Changes from baseline in parasite load (GM Ratio (95%CI)) | |||||
| D8 | 1·30(0·78;2·16) | 0·17(0·10;0·28) | 0·09(0·06;0·16) | 0·13(0·08;0·22) | 0·10(0·06;0·17) |
| D15 | 0·81(0·54;1·20) | 0·11(0·07;0·23) | 0·07(0·05;0·11) | 0·09(0·06;0·14) | 0·07(0·05;0·10) |
| D36 | 0·77(0·56;1·06) | 0·06(0·05;0·09) | 0·07(0·05;0·09) | 0·07(0·05;·009) | 0·07(0·05;0·09) |
| EOT (D65) | 0·70(0·49;0·96) | 0·06(0·05;0·09) | 0·07(0·05;0·09) | 0·07(0·05;0·09) | 0·07(0·05;0·09) |
| 4 months | 0·67(0·40;1·12) | 0·12(0·07;0·20) | 0·45(0·27;0·76) | 0·11(0·06;0·18) | 0·07(0·04;0·11) |
| 6 months | 1·08(0·61;1·92) | 0·31(0·18;0·55) | 0·25(0·14;0·46) | 0·19(0·11;0·36) | 0·07(0·04;0·12) |
| 12 months | 0·91(0·50;1·66) | 0·69(0·38;1·23) | 1·05(0·58;1·92) | 0·22(0·12;0·42) | 0·07(0·04;0·12) |
| p-value for comparison against placebo at 12 months* | 0·499 | 0·744 | 0·001 | <0·001 | |
| Changes from baseline in conventional ELISA (mean diff (95%CI)) | |||||
| D36 | -0·05 (-0·17;0·08) | -0·03 (-0·15;0·09) | 0·12 (-0·01;0·24) | -0·06 (-0·19;0·07) | -0·119 (-0·24;0·01) |
| EOT (D65) | -0·07 (-0·19;0·05) | -0·02 (-0·14;0·1041) | 0·08 (-0·05;0·20) | -0·086 (-0·21;0·04) | -0·08 (-0·20;0·05) |
| 4 months | -0·14 (-0·26;-0·02) | -0·031 (-0·15;0·09) | -0·03 (-0·15;0·09) | 0·018 (-0·11;0·15) | -0·05 (-0·18;0·08) |
| 6 months | -0·03 (-0·15;0·08) | -0·042 (-0·15;0·07) | 0·02 (-0·10;0·13) | -0·037 (-0·16;0·08) | -0·09 (-0·21;0·02) |
| 12 months | -0·15 (-0·28;-0·03) | -0·192 (-0·31;-0·07) | -0·05 (-0·18;0·08) | -0·044 (-0·18;0·09) | -0·14 (-0·27;-0·01) |
| p-value for comparison against placebo at 12 months* | 0·670 | 0·254 | 0·233 | 0·868 | |
| Changes from baseline in AT CL-ELISA (mean diff (95%CI)) | |||||
| D36 | 0·04 (-0·02;0·11) | -0·00 (-0·06;0·06) | 0·02 (-0·04;0·09) | -0·01 (-0·07;0·05) | 0·05 (-0·01;0·11) |
| EOT (D65) | 0·01 (-0·06;0·08) | -0·02 (-0·09;0·05) | -0·01 (-0·08;0·06) | -0·04 (-0·11;0·03) | 0·02 (-0·05;0·09) |
| 4 months | -0·01 (-0·07;0·05) | 0·03 (-0·02;0·09) | 0·02 (-0·05;0·08) | -0·03 (-0·09;0·03) | -0·01 (-0·07;0·05) |
| 6 months | -0·02 (-0·09;0·05) | 0·02 (-0·04;0·09) | -0·02 (-0·09;0·05) | -0·05 (-0·13;0·02) | 0·02 (-0·05;0·09) |
| 12 months | -0·02 (-0·08;0·05) | -0·02 (-0·09;0·04) | 0·03 (-0·03;0·09) | 0·04 (-0·02;0·11) | -0·01 (-0·07;0·05) |
| p-value for comparison against placebo at 12 months* | 0·835 | 0·321 | 0·192 | 0·894 | |
| Estimate of geo. mean (95% CI) | 3·01 (2·60, 3·47) | 2·85 (2·47, 3·27) | 2·85 (2·46, 3·29) | 2·55 (2·19, 2·96) | 2·44 (2·11, 2·83) |
| Estimate of geo. mean ratio: treament/placebo (95% CI) | 0·95 (0·77, 1·16) | 0·95 (0·77, 1·16) | 0·85 (0·69, 1·04) | 0·81 (0·66, 0·1) | |
| p-value for ratio to placebo* | 0·593 | 0·596 | 0·1210 | 0·049 | |
EOT, end of treatment.
*
Estimates from repeated measures linear model with treatment, baseline, sample, treatment by sample and baseline by sample interactions